SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness

Abstract In order to support vaccine development, and aid convalescent plasma therapy, it would be important understand the kinetics, timing persistence of SARS-CoV-2 neutralizing antibodies (NAbs), their association with clinical disease severity. Therefore, we used a surrogate viral neutralization test evaluate levels in patients varying severity illness, those prolonged shedding mild/asymptomatic illness at various time points. Patients severe or moderate COVID-19 had earlier appearance NAbs higher compared mild asymptomatic illness. Furthermore, who virus, appearing faster than cleared virus earlier. During first week NAb was significantly less (p = 0.01), At end 4 weeks (28 days), although 89% NAbs, 38/76 (50%) > 90 days negative result for presence NAbs. The Ab declined during convalescence (> since onset illness), 8 Our data show that high early associated these 50% individuals after 3 months